First Manhattan’s Heron Therapeutics HRTX Stock Holding History

First Manhattan’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300	Closed	–	–	1576
2022 Q2	$0	Hold	300	–	–	﹤0.01%	1603
2022 Q1	$1K	Hold	300	–	–	﹤0.01%	1539
2021 Q4	$2K	Hold	300	–	–	﹤0.01%	1477
2021 Q3	$3K	Hold	300	–	–	﹤0.01%	1479
2021 Q2	$4K	Buy	+300	New	+$4.77K	﹤0.01%	1430
2021 Q1	–	Sell	-40	Closed	–	–	1507
2020 Q4	$0	Hold	40	–	–	﹤0.01%	1364
2020 Q3	$0	Hold	40	–	–	﹤0.01%	1382
2020 Q2	$0	Hold	40	–	–	﹤0.01%	1413
2020 Q1	$0	Buy	+40	New	+$752	﹤0.01%	1403

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

First Manhattan's HRTX Position: Q3 2022 in Review

First Manhattan sold out of Heron Therapeutics (HRTX) in Q3 2022, closing a stake of 300 shares.

First Manhattan first reported a position in HRTX in Q1 2020 and held it in 9 quarters. The position peaked at $4K in Q2 2021. 186 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

First Manhattan reported no remaining Heron Therapeutics position as of Q3 2022 after selling out during the quarter.
First Manhattan sold 300 Heron Therapeutics shares in Q3 2022.
First Manhattan first reported a position in Heron Therapeutics in Q1 2020 and held it in 9 quarters.
First Manhattan's Heron Therapeutics position peaked at $4K in Q2 2021.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on First Manhattan's 13F filing for Q3 2022, filed 14 Nov 2022.